Compare Super Micro Computer Inc (SMCI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Super Micro Computer Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Super Micro Computer Inc trades at $34.59 (market cap $25.67B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Super Micro Computer Inc is far larger — about 5.3× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Super Micro Computer Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Super Micro Computer Inc for 20 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SMCI | TVTX | |
|---|---|---|
Market Cap | $25.67B | $4.88B |
Volume | 24,555,322 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $55.04 | $67.52 |
52-Week Low | $20.53 | $26.79 |
Typical Hold Time | 20 Days | 0 Days |
Enterprise Value | $31.13B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $39.07, down 2.28% today, with a bullish technical signal and strong fundamental growth. The stock shows robust earnings beats, with Q2 2026 EPS of $1.70 exceeding the $0.923 estimate, and revenue is projected to grow from $22.0B in 2025 to $39.1B in 2026. Analyst consensus is a $42.33 price target, with 36% buy ratings. Recent news highlights AI-driven order surges and new NVIDIA Vera Rubin shipments, supporting positive sentiment amid competitive pressures.
The outlook for SMCI is positive, driven by AI infrastructure demand and earnings momentum, but risks include margin pressure and a Department of Justice investigation. Valuation remains attractive with a P/E of 11.98, though debt levels and market volatility warrant caution. Upside potential exists if the company maintains its growth trajectory and navigates legal challenges.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Super Micro Computer Inc
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
